Your browser doesn't support javascript.
loading
A pilot evaluation of the expanded prostate cancer index composite for clinical practice (EPIC-CP) tool in Ontario.
Brundage, M D; Barbera, L; McCallum, F; Howell, D M.
Afiliação
  • Brundage MD; Division of Cancer Care and Epidemiology, Queen's Cancer Research Institute, Queen's University, Kingston, ON, Canada. Michael.brundage@kingstonhsc.ca.
  • Barbera L; Clinical Department of Oncology, Cancer Control Alberta, Alberta Health Services, Calgary, AB, Canada.
  • McCallum F; Patient Reported Outcomes and Symptom Management, Cancer Care Ontario, Toronto, ON, Canada.
  • Howell DM; Psychosocial Oncology and Supportive Care, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Qual Life Res ; 28(3): 771-782, 2019 Mar.
Article em En | MEDLINE | ID: mdl-30382479
PURPOSE: To introduce the EPIC-CP symptom screening tool in routine ambulatory cancer care, and to evaluate its acceptability and perceived usefulness from the perspective of patients and clinicians. METHODS: Eligible prostate cancer patients from four cancer centres were recruited (November 2014-June 2015) from radiation or surgical oncology clinics. A physician and/or health care professional reviewed the EPIC-CP results as part of the clinical encounter. Patient experience with the tool was evaluated using a nine-item Patient Exit Survey (PES). Clinician experience was evaluated through semi-structured qualitative interviews. Patient and clinician results were compared to identify common themes. RESULTS: A total of 333 patients were enrolled, of whom, 287 completed the PES. Most patients had one clinical encounter, although the number of EPIC-CP assessments ranged from 1 to 11 per patient, for a total of 937 EPIC-CP questionnaires completed. Item completion rates were high (91-100%), with items addressing sexual health among the lowest (91-92%). On the PES, most patients (70%) agreed with the item: "Completing this questionnaire helped me tell the clinicians about how I have been feeling". Thematic analysis from clinician interviews revealed that the EPIC-CP captures essential prostate-specific effects that facilitated person-centred communication and customization of interventions. Targeted clinical education and patient resources were seen as necessary for uptake. CONCLUSIONS: EPIC-CP was generally endorsed by clinicians and patients. The implementation of a disease-specific measure in place of a generic symptom screening tool has the potential to improve the quality of the clinical encounter and provide outcome measures for further health services research. Provincial implementation of this tool as a standard of care is recommended.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Qualidade de Vida / Avaliação de Resultados em Cuidados de Saúde / Medidas de Resultados Relatados pelo Paciente Tipo de estudo: Clinical_trials / Evaluation_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Limite: Adult / Aged / Aged80 / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Qualidade de Vida / Avaliação de Resultados em Cuidados de Saúde / Medidas de Resultados Relatados pelo Paciente Tipo de estudo: Clinical_trials / Evaluation_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Limite: Adult / Aged / Aged80 / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Ano de publicação: 2019 Tipo de documento: Article